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Abstract
Aims/hypothesis Type 2 diabetes is characterised by
progressive beta cell dysfunction, with changes in gene
expression playing a crucial role in its development.
MicroRNAs (miRNAs) are post-transcriptional regulators of
gene expression and therefore alterations in miRNA levels
may be involved in the deterioration of beta cell function.
Methods Global TaqMan arrays and individual TaqMan
assays were used to measure islet miRNA expression in
discovery (n =20) and replication (n =20) cohorts from
individuals with and without type 2 diabetes. The role of
specific dysregulated miRNAs in regulating insulin secretion,
content and apoptosis was subsequently investigated in
primary rat islets and INS-1 cells. Identification of miRNA
targets was assessed using luciferase assays and by measuring
mRNA levels.
Results In the discovery and replication cohorts miR-187
expression was found to be significantly increased in islets
from individuals with type 2 diabetes compared with matched
controls. An inverse correlation between miR-187 levels and
glucose-stimulated insulin secretion (GSIS) was observed in
islets from normoglycaemic donors. This correlation
paralleled findings in primary rat islets and INS-1 cells where
overexpression of miR-187markedly decreased GSIS without
affecting insulin content or apoptotic index. Finally, the gene
encoding homeodomain-interacting protein kinase-3
(HIPK3 ), a known regulator of insulin secretion, was
identified as a direct target of miR-187 and displayed reduced
expression in islets from individuals with type 2 diabetes.
Conclusions/interpretation Our findings suggest a role for
miR-187 in the blunting of insulin secretion, potentially
involving regulation of HIPK3 , which occurs during the
pathogenesis of type 2 diabetes.
Keywords Glucose-stimulated insulin secretion . HIPK3 .
Islets . MicroRNA . Type 2 diabetes
Abbreviations
GSIS Glucose-stimulated insulin secretion
HIPK3 Homeodomain-interacting protein kinase-3
miRNA MicroRNA
sn Small nuclear
Introduction
In type 2 diabetes the inability of beta cells to compensate for
reduced insulin sensitivity is associated with specific changes
in gene expression, which may conceivably play a causal role
in beta cell dysfunction. MicroRNAs (miRNAs) are a class of
small non-coding RNAs that regulate gene expression by
binding to target mRNAs, resulting in mRNA decay and/or
translational repression. There is growing evidence that
changes in the expression of miRNAs can affect beta cell
function (reviewed by Guay et al [1]). Recent evidence has
suggested that changes in miRNA expression may either
precede diabetes onset, and be associated with positive effects
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on beta cell function, or occur on manifestation of the disease
and impact negatively on beta cell function [2, 3]. Indeed, a
comparison of the islet miRNome of the Goto–Kakizaki (GK)
rat model of type 2 diabetes, withWistar controls, has revealed
a set of upregulated miRNAs enriched in targets within
pathways known to be involved in disease causation [4]. In
the present study we hypothesised that a similar strategy,
measuring the expression of miRNAs in human islets from
individuals with and without type 2 diabetes, might identify
specific miRNAs with a causal role in human beta cell
dysfunction.
Methods
Human islet tissue For global miRNA profiling snap-frozen
human islets were received from three centres (National
Disease Research Interchange, Philadelphia, PA, USA; AMS
Biotechnology, Abingdon, UK; and ProCell Biotech,
Newport Beach, CA, USA). All islets were taken with
approval from appointed ethics committees. For replication
all islets came from ProCell Biotech. Islet purity and viability
were determined by dithizone and fluorescein diacetate/
propidium iodide staining, respectively [5, 6]. Islets from
ProCell Biotech were provided with information regarding
glucose-stimulated insulin secretion (GSIS), determined as
follows. After isolation and overnight culture islets were
incubated sequentially in media containing low (2.8 mmol/l)
and high (28 mmol/l) glucose for 1 h. The amount of insulin
present in each supernatant fraction was measured by
electrochemiluminescence immunoassay on a Cobas e601
analyser (Roche, Indianapolis, IN, USA). GSIS was
calculated as insulin secretion at 28 mmol l−1/2.8 mmol l−1
glucose.
Isolation and culture of primary rat islets and INS-1 cells The
rat insulinoma cell line INS-1 was cultured in RPMI
1640 GlutaMAX (Life Technologies, Paisley, UK) media
supplemented with 10% FCS, 100 U/ml penicillin, 100
μg/ml streptomycin and 100 μmol/l β-mercaptoethanol.
Primary rat islets were isolated by collagenase digestion
[7], hand-picked and cultured, prior to transfection, for
at least 24 h in RPMI 1640 medium containing
10 mmol/l glucose, 10% FCS, 100 U/ml penicillin and
100 μg/ml streptomycin.
RNA extraction and real-time quantitative PCR Total RNA,
including miRNA, was extracted using the miRVana miRNA
isolation kit (Life Technologies). MiRNA reverse
transcription reactions were carried out using the miRNA
reverse transcription kit (Life Technologies). For global
profiling human TaqMan arrays (version 2.0, cards A + B
containing assays to 667 miRNAs; Life Technologies) were
used with a pre-amplification step included, following the
manufacturers’ instructions. Values for Ct were generated
using automatic settings, ΔCt was calculated using a global
mean normalisation strategy [8], andΔΔCt for each gene was
determined using a mean ΔCt value in control samples.
Profiling of miR-187, miR-345, miR-15b and U6 small
nuclear (sn)RNA was conducted using inventoried TaqMan
miRNA assays (Life Technologies) with expression
determined from three separate reverse transcription reactions.
For the measurement of rat Hipk3 and human HIPK3
expression, RNA was reverse transcribed using SuperScript
III First-Strand Synthesis System (Life Technologies) with
oligo-dT priming. For rat Hipk3 expression RNA was, prior
to reverse transcription, DNased using the Turbo DNA-free
kit (Life Technologies). TaqMan Gene Expression Assays
(Life Technologies) were used to measure expression of
Hipk3 (Rn00582409_m1) and HIPK3 (Hs00178628_m1).
Expression was normalised using GeNorm [9], with the
following housekeeping genes measured where appropriate;
Ubc (Rn01789812_g1), Tbp (Rn01455648_m1), Hprt1
(Rn01527840_m1) , B2M (Hs00984230) , GUSB
(Hs00939627) and RPLP0 (Hs99999902_m1). Relative
expression was calculated using the comparative Ct method.
All reactions were run on an ABI7900HT platform (Life
Technologies).
INS-1 transfection and measurement of insulin secretion and
beta cell apoptosis Transient transfection of INS-1 cells, at a
density of ~2×106 cells, was conducted with miRVana
miRNA mimics (Life Technologies) and a Nucleofector
Device (Lonza, Basel, Switzerland). Negative Control
miRVana miRNA mimic number 1 (Life Technologies),
which has been designed not to target any known human,
mouse or rat gene, was used as a negative control. Transfected
cells were plated in 24-well poly-D-lysine-coated plates at a
density of ~3×105 cells/well. After 48 h, media were removed
and cells washed once and then incubated for 2 h in modified
Krebs–Ringer medium (125 mmol/l NaCl, 4.74 mmol/l KCl,
1 mmol/l CaCl2, 1.2 mmol/l KH2PO4, 1.2 mmol/l MgSO4,
5 mmol/l NaHCO3 and 25 mmol/l Hepes, pH 7.4) containing
0.1% BSA and 2.8 mmol/l glucose. Cells were then subjected
to either high (28 mmol/l) or low (2.8 mmol/l) glucose
treatment for 1 h before the supernatant fraction was removed
for insulin determination. Levels of insulin were measured by
radioimmunoassay (Linco Research, St Charles, MO, USA)
and normalised to protein content as determined by BCA
assay (Pierce, Rockford, IL, USA). For the analysis of INS-1
apoptosis 48 h post-transfection the ApopTag Fluorescein
Direct In Situ Apoptosis Detection Kit (Millipore, Billerica,
MA, USA) was used according to the manufacturer’s
instructions. Samples were co-stained with DAPI, mounted
in VectorShield (Vector Laboratories, Peterborough, UK) and
viewed using a Zeiss AxioObserver Z1 microscope (Carl
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Zeiss, Oberkochen, Germany) equipped with a ×40 1.3
numerical aperture (NA) oil objective and controlled by
AxioVision software (Carl Zeiss) As a positive control
untransfected cells were heat shocked at 56°C for 3 min.
The cells were allowed to recover at 37°C for 1 h before the
assay was performed. Heat shock induced ~40% of cells to
become apoptotic (data not shown).
Primary rat islet transfection and measures of insulin
secretion and beta cell apoptosis Transfections were carried
out using TransIT-TKO (Mirus Bio Corporation, Madison,
WI, USA) in the presence of 1 nmol/l miRVana miRNA
mimic (Life Technologies) for 48 h prior to assays. Insulin
secretion was determined as previously described [10] with
insulin content assayed following acidified ethanol
extraction. We note that while transfection of the intact islet
is likely to affect only the outermost layers of cells [11] it is
from these that the majority of stimulated insulin secretion
is likely to be observed in vitro given the loss of islet
vasculature which occurs rapidly during culture [12]. For
the analysis of apoptosis, islets were fixed in 4%
paraformaldehyde and stained using the DeadEnd
fluorometric TUNEL system (Promega, Madison, WI,
USA), as per the manufacturer’s protocol for non-adherent
cells. Following nicked end labelling using the kit, islets
were washed in PBS and then incubated overnight at 4°C
with guinea pig anti-insulin antibody (1:200; Dako,
Glostrup, Denmark) in PBS containing 0.1% Triton
X-100 and BSA. Islets were then washed and incubated in
goat anti-guinea pig Alexa Fluor 568 (1:1,000; Life
Technologies) in PBS for 1 h at room temperature.
Subsequently, islets were washed twice in PBS and spotted
on superfrost slides. The slides were left to set overnight in
Vectashield HardSet Mounting Medium with DAPI (Vector
Laboratories, Burlingame, CA, USA) at room temperature
in the dark. Islets were imaged using a Zeiss Axiovert-200
confocal microscope with an Improvision/Nokigawa
spinning disc, and running Volocity 5.0 (Improvision,
Coventry, UK) software. Image analysis was performed
using ImageJ v.1.43m (http://rsbweb.nih.gov/ij/download.
html).
Luciferase assay The pMirTarget plasmids containing the 3′
UTR of human HIPK3 (NM_001048200) downstream of
firefly luciferase, and a mutant version differing only by a
C-to-G substitution (underlined) within the predicted miR-
187 binding site (UUCUAACUAGUGCAAGACACGU),
were purchased (Origene, Rockville, MD, USA). Luciferase
activities were measured using the Dual-Glo Luciferase Assay
System (Promega). To account for differences in transfection
efficiency firefly luciferase activity was normalised to Renilla
expression which originated from co-transfected pRL-SV40
(Promega).
Statistical analysis Except where stated otherwise, statistical
differences were assessed using two-tailed one-sample or two-
sample t tests, with correction for multiple testing as indicated.
A p value <0.05 was considered significant. All data are
presented as mean ± SEM.
Results
miR-187 expression is increased in islets from donors with
type 2 diabetes The global miRNA profile of islets from 20
donors (11with type 2 diabetes, nine controls) was determined
using TaqMan arrays. Of the 667 miRNA assays on these
arrays 255 amplified in all samples (electronic supplementary
material [ESM] Table 1) and the use of pre-amplification
meant we decided to limit our analysis to these miRNAs (we
found many ‘on/off’ changes in expression, most likely due to
inconsistent amplification of very weakly expressed
miRNAs). Two miRNAs, miR-187 and miR-345, displayed
higher and statistically significant (after Benjamini–Hochberg
false discovery rate correction) differential expression
between islets from donors with and without type 2 diabetes
(Table 1).
We next sought to replicate our results in an independent
cohort using individual miRNA-specific TaqMan assays. We
measured the expression of miR-345 and miR-187 in another
20 islet samples (ten from individuals with type 2 diabetes, ten
without diabetes) and again found significantly higher
miR-187 expression in islets from donors with type 2 diabetes
vs healthy donors. The increase in miR-345 islet expression
observed in individuals with type 2 diabetes in the initial
cohort did not replicate (Table 1). No significant differences
in age, sex, BMI, ethnicity, islet purity or islet viability
between groups were identified in either islet cohort. Also
consistent with previous findings [13] and with a primary role
for reduced GSIS in disease pathogenesis, islets in the
replication cohort from individuals with type 2 diabetes
displayed reduced glucose-stimulated insulin release when
compared with islets from individuals without diabetes
(Table 2).
miR-187 expression is inversely correlated with GSIS Given
the observed increase in miR-187 expression in both islet
cohorts we investigated whether this miRNA might play a
role in islet function or survival. In islets from 35
normoglycaemic donors we found a significant inverse
correlation between miR-187 expression and GSIS (Fig. 1a).
No significant correlation was found between levels of miR-15b
and GSIS (data not shown), despite levels being similarly
normalised to U6 snRNA.
Overexpression of miR-187 in islets and beta cells reduces
GSIS To determine whether increased miR-187 expression
Diabetologia
might contribute directly to reduced GSIS, miR-187 mimics or
control sequences were transiently transfected into primary rat
islets. Compared with mimic-control-transfected islets the
introduction of miR-187 mimics sharply reduced insulin
secretion stimulated by high (20 mmol/l) glucose and to a far
lesser, albeit significant degree, on KCl stimulation (Fig. 1b).
There were no significant differences in insulin content between
miR-187 and mimic-control-transfected islets (Fig. 1c).
We next tested whether the above actions of miR-187 were
likely to be through a cell-autonomous effect of miR-187 on
beta cells within the islet. Correspondingly, measured in the
rat pancreatic beta cell line, INS-1, near-physiological levels
of miR-187 overexpression (ten- to 20-fold increase in cells
transfected with miR-187 compared with mimic control; ESM
Fig. 1a) also resulted in a significant reduction in insulin
secretion under high (28 mmol/l) but not low (2.8 mmol/l)
glucose conditions, compared with cells transfected with
mimic control (ESM Fig. 1b).
Transfection of miR-187 mimic into primary rat islets and
INS-1 cells resulted in no significant difference in rates of
apoptosis, as assessed by TUNEL assay, when compared with
mimic-control-transfected cells (ESM Fig. 2), and no evident
effects on cell viability as judged through overall cellular
morphology (data not shown).
HIPK3 is a direct target of miR-187 In order to identify
putative miR-187 targets we used miRWalk[14], a database
that compiles results frommultiple commonly used prediction
programs (TargetScan, miRanda, miRDB and RNA22). One
of the putative targets identified was the gene encoding
homeodomain-interacting protein kinase-3 (HIPK3), a known
regulator of insulin secretion [15]. Strikingly, the blunted
insulin secretory responses at high glucose concentrations in
Hipk3−/− mice, or on small interfering (si)RNA-mediated
knockdown of HIPK3 in isolatedmouse islets [15], are similar
to the phenotype we observe on miR-187 overexpression.
Table 1 Results of miRNA expression profiling in human islets from individuals with and without type 2 diabetes
miRNA Global TaqMan array profiling Individual TaqMan assay profiling
Relative expressiona Unadjusted p value Adjusted p valueb Relative expressiona Unadjusted p value
miR-187 7.55 7×10−5 0.009 5.38 0.021
miR-345 1.92 2×10−5 0.006 0.64 0.112
miR-129-3p 3.32 0.002 0.115 ND ND
aCalculated using the formula: mean expression in those with type 2 diabetes/mean expression in controls
b Adjusted using Benjamini–Hochberg false discovery rate
Statistical significance determined using two-sample t tests and Fisher’s exact test
ND, not determined
Table 2 Clinical characteristics of donors in discovery and replication cohorts
Characteristic Global TaqMan array profiling Individual TaqMan assay profiling
T2D islets Control islets p value T2D islets Control islets p value
n 9 11 – 10 10 –
Sex (male/female) 7/2 5/6 0.20 3/7 5/5 0.65
Ethnicity (white/African–American/Asian) 5/2/2 9/2/0 0.19 4/6/0 9/1/0 0.06
Age (years) 53 (8) 47 (9) 0.09 55 (9) 51 (6) 0.24
BMI 36 (14) 30 (6) 0.27 32 (4) 29 (5) 0.08
Islet purity (%) 81 (8) 82 (10) 0.94 89 (5) 90 (5) 0.51
Islet viability (%) 90 (6) 88 (8) 0.58 91 (2) 92 (2) 0.30
Cold ischaemic time (h) 14 (7) 16 (5) 0.54 16 (6) 15 (6) 0.61
GSISa ND ND – 2.6 (1.3) 4.2 (1.4) 0.02
a Calculated using formula: insulin secretion at 28 mmol/l glucose/insulin secretion at 2.8 mmol/l glucose
Where appropriate, data presented as mean (SD)
Statistical significance determined using two-sample t tests and Fisher’s exact test
ND, not determined; T2D, type 2 diabetes
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To explore the possibility that HIPK3 may be regulated by
miR-187 we first measuredHipk3 mRNA levels in INS-1 cells
transfected with miR-187 mimic and mimic control. The
putative miR-187 binding site is conserved from human to
rat so a decrease in Hipk3 expression was expected. Indeed,
as determined by real-time qPCR, Hipk3 mRNA levels were
significantly reduced in INS-1 cells transfected with miR-187
mimic compared with mimic-control-transfected cells
(Fig. 2a). Furthermore, overexpression of miR-187 in INS-1
cells significantly inhibited the expression of a construct in
which the 3′ UTR sequence of human HIPK3 was fused
downstream of luciferase cDNA. This inhibition was not seen
when the predicted miR-187 target sequence was mutated,
indicating a direct interaction between miR-187 and the 3′
UTR of human HIPK3 (Fig. 2b). Subsequent measurement
ofHIPK3 transcripts in the islets comprising the discovery and
replication cohorts for the miRNA profiling also revealed a
reduction of HIPK3 mRNA expression in islets from
individuals with type 2 diabetes vs those without (Fig. 2c).
Discussion
Despite concerns regarding the effect of hyperglycaemia on
transcript levels, differential mRNA expression in human
islets from donors with type 2 diabetes vs those without
diabetes can successfully identify genes with a causal role in
beta cell dysfunction [16]. Using a similar global profiling
approach we have identified a specific miRNA, miR-187,
with reproducibly higher expression in islets from donors with
type 2 diabetes. We have consequently elucidated a role for
miR-187 in regulating insulin secretion, possibly through
direct targeting of HIPK3 .
Many previous studies describing differential islet gene
expression from individuals with and without type 2 diabetes
have been plagued by a failure to replicate. One of the
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Fig. 1 Increased miR-187 expression is associated with reduced GSIS.
(a) In islets from 35 non-diabetic donors higher levels of miR-187
expression correlated with reduced GSIS (calculated as amount of insulin
secreted at 28 mmol l−1/amount of insulin secreted at 2.8 mmol l−1).
miRNA expression was determined from three separate reverse
transcriptions using real-time PCR. Statistical significance was assessed
by the Pearson correlation coefficient test; r =−0.34, p =0.049. (b )
Compared with mimic-control-transfected cells, the introduction of
miR-187 mimic into primary rat islets reduced insulin secretion under
high glucose (20 mmol/l) conditions. **p <0.01 and *p <0.05 vs cells
transfected with mimic control, n =3 independent experiments. Black,
control; grey, miR-187. (c) No significant difference in insulin content in
primary rat islets transfected with control and miR-187 mimics, n =3
independent experiments. All data expressed as mean ± SEM
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Fig. 2 HIPK3 is a direct target of miR-187. (a) In INS-1 cells transfected
with miR-187 mimic endogenous Hipk3 mRNA expression is reduced,
*p <0.05 vs cells transfected with negative control miRNA mimic.
Statistical significance assessed by one-tailed one-sample t test, n =8
independent experiments. (b) In INS-1 cells overexpression of miR-187
inhibited luciferase expression from a construct containing the 3′ UTR
sequence of human HIPK3 (WT), but not expression from a construct
containing the 3′ UTR sequence of human HIPK3 where the putative
miR-187 binding site has been mutated (MT). Statistical significance
assessed by one-sample t test; n =4 independent experiments. Black,
control; grey, miR-187. (c)HIPK3 mRNA expression is reduced in islets
from individuals with type 2 diabetes (T2D) (n=17) compared with islets
from matched controls (n =18). Statistical significance assessed by two-
sample t test. All data presented as mean ± SEM
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strengths of our study was the use of a second islet cohort, the
prudence of such an approach highlighted by differential miR-
345 expression not replicating. A failure to match groups for
age, BMI, sex, ethnicity, islet purity and viability can also lead
to spurious results. In the present study there were no significant
differences in such confounding factors, all of which can
influence mRNA expression [17, 18], and are likely to affect
miRNA expression. Theremay, of course, be other confounders
we were unable to control for in the present study. For example,
changes in the cellular composition of the islets (i.e. alpha/beta
cell ratios) cannot be excluded, though this would seem to be
unlikely. Future studies, involving even larger islet cohorts,
seem very likely to find further aberrantly expressed miRNAs
in islets from individuals with type 2 diabetes; however, our
study provides proof-of-principle that miRNA expression
profiling in islets from individuals with and without diabetes
can identify miRNAswith a causal role in beta cell dysfunction.
Using direct functional assays in both primary rodent islets
and a rat insulinoma-derived cell line, we provide evidence
here that increases in miR-187 affect glucose- and, to a lesser
extent, depolarisation-induced insulin secretion, without
evident effects on cell viability or apoptotic index.
Importantly, the dramatic inhibition of GSIS elicited by
miR-187 was similar in extent to what we observed after
transfection with a mimic of miR-375 (data not shown).
MiR-375 has a well-established role in the control of insulin
release [19] and our results suggest that miR-187 may play an
equally important role in this process after its induction in the
beta cell of individuals with type 2 diabetes. Given the much
greater impact of miR-187 overexpression on glucose-
compared with KCl-stimulated secretion, it would appear that
miR-187 acts chiefly on events upstream of membrane
depolarisation, potentially impairing glucose metabolism or
increases in free cytosolic Ca2+ [20]. Detailed future studies
will be needed to investigate these possibilities. Likewise,
analysing the effects of overexpressing miR-187 in primary
human islets and in response to additional physiological
secretagogues (such as glucagon-like peptide-1, acetylcholine
and amino acids) also represent important future experiments.
By providing one possible mechanism through which miR-
187 may act we show here that HIPK3 is a target for this
miRNA in the beta cell. Importantly, HIPK3 has recently been
shown to be required for the normal stimulation of insulin
secretion by glucose. Thus, Hipk3− /− mice are glucose
intolerant and show depressed islet levels of two keymediators
of glucose responsiveness: pancreatic duodenum homeobox-1
(PDX1) and phosphorylated glycogen synthase kinase-3 β
(GSK3β) [15]. Although we observed only small decreases
in luciferase activity and Hipk3 transcript levels on miR-187
overexpression, this is consistent with a role for miRNAs in
fine-tuning gene expression [21, 22]. Additionally, given that
in mouse islets a modest 46% knockdown of HIPK3 reduces
insulin secretion at 20 mmol/l to 54% of that seen in control
cells [15], it seems plausible that small decreases in Hipk3
expression may have a significant impact on GSIS. We
emphasise that while the decrease in Hipk3 mRNA levels in
the presence of miR-187 may conceivably be compounded by
a decrease in translational efficiency, recent studies suggest
that the actions of miRNAs are largely (~84%) mediated by
RNA degradation [23]. Nonetheless, studies are needed to
explore this possibility.
Aberrant miR-187 expression has, to our knowledge, not
been reported in any previous study examining miRNA
expression in islets from animal models of type 2 diabetes,
nor in cell-line models using culture conditions that mimic
those found in an individual with diabetes. While evidence of
deregulated miR-187 expression in these experiments might
strengthen and support our data it is perhaps not surprising,
given the difficulties in modelling polygenic diseases in
controlled animal and cell culture systems, that no such result
has been reported previously. Indeed, the molecular
mechanisms through which miR-187 expression is increased
in islets from donors with type 2 diabetes remain obscure.
It is interesting that two recent studies detailing the human
islet miRNome in individuals without diabetes report either
low miR-187 expression [24] or a failure to detect miR-187 in
the majority of samples studied [25] (it is assumed that ΔCt
values and normalised RNA-Seq read counts can be used as
appropriate proxies for absolute miRNA levels). We also find
that miR-187 is relatively weakly expressed in individuals
without diabetes. However, the five- to sevenfold increase in
miR-187 expression in islets from individuals with type 2
diabetes means its levels in this pathophysiological state are
comparable with, or greater than, levels of several other
miRNAs with known roles in beta cell function (miR-29b
[26], miR-9 [27] and miR-96 [28]). Perhaps, akin to what
has been assumed to account for the relatively low steady-
state expression of other regulatory genes (such as
transcription factors) [29], a low expression of miR-187 is
needed to provide a built-in fail-safe mechanism, controlling
its persistence and thus preventing aberrant beta cell function.
We are aware of only one other publication comparing
miRNA expression in human islets from individuals with
and without glucose intolerance. While using a far smaller
number of samples than the present study (n =9 islets from
individuals without diabetes, n =6 from individuals with an
HbA1c≥6.1), and also examining the expression of only a
small number of miRNAs (not including miR-187), this
earlier study provided some evidence for abnormal miRNA
expression in islets from individuals with type 2 diabetes [30].
The results of our larger study highlight that aberrantly
expressed miRNAs may be causally involved in human islet
dysfunction during type 2 diabetes. Future studies identifying
further dysregulated miRNAs may discover novel pathways
involved in islet dysfunction that could provide novel
therapeutic targets for diabetes treatment.
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